The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Open accessAbstract
Purpose: To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS). Patients and Methods: Thirty-six patients received cetuximab (initial dose of 400 mg/m 2 followed by subsequent weekly doses of 250 mg/m 2 ) for at least 6 weeks with a 48-week follow-up. The primary end point was the disease control rate (DCR) at 6 weeks (according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria). Secondary end points included best response rate, overall survival, progression-free survival (PFS), and toxicity assessment. Association of treatment efficacy with RAS mutations or FcγR genotypes was investigated. Results: Median age of the study population was 79 years. DCR at 6 weeks was obtained in 25 of 36 patients (69%; 95% CI, 52% to 84%) of the intention-to-treat population. The best responses were eight partial responses and two complete responses. There were no cetuximab-related deaths. There were three related serious adverse events: two grade 4 infusion reactions and one grade 3 interstitial pneumopathy. Grade 1 to 2 acne-like rash occurred in 78% of patients and was associated with prolonged PFS. One HRAS mutation was identified. Combined FcγRIIa-131H/H and/or FcγRIIIa-158V/V polymorphisms were not associated with the clinical outcomes. Conclusion: As a first-line treatment in patients with unresectable SCCS, cetuximab achieved 69% DCR. A randomized phase III trial is warranted to confirm that cetuximab may be considered as a therapeutic option especially in elderly patients. The low frequency of RAS mutations in SCCS makes SCCS tumors attractive for EGFR inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Cutaneous Squamous-Cell Carcinoma
Alam, M., & Ratner, D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441306 · Cited by 1,305
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Cited by
Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma
Ji, A. L., Rubin, A. J., Thrane, K., Jiang, S., Reynolds, D. L., Meyers, R. M., Guo, M. G., George, B. M., Mollbrink, A., Bergenstråhle, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.039 · Cited by 1,117
“Along those lines, the observed co-essentiality coupling of EGFR, which is broadly expressed in tumors, to the integrin signaling network nominates combined inhibition of EGFR and integrin signaling for treatment of advanced cSCC (Figure 7G) (Maubec et al., 2011).”
BackgroundStratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Concetta Fargnoli, M., Forsea, A. M., Frenard, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.008 · Cited by 319
Keeping, S., Xu, Y., Chen, C.-I., Cope, S., Mojebi, A., Kuznik, A., Konidaris, G., Ayers, D., Sasane, M., Allen, R., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-0823 · Cited by 51
Metadata
- Authors
- Maubec, E., Petrow, P., Scheer-Senyarich, I., Duvillard, P., Lacroix, L., Gelly, J., Certain, A., Duval, X., Crickx, B., Buffard, V., Basset-Seguin, N., Saez, P., Duval-Modeste, A.-B., Adamski, H., Mansard, S., Grange, F., Dompmartin, A., Faivre, S., Mentré, F., & Avril, M.-F.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-09-01
- Volume
- 29
- Issue
- 25
- Pages
- 3419-3426
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155752258
- Cited by
- 470
- References
- 32
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. https://app.cochat.ai/papers/10.1200/jco.2010.34.1735
- The paper
- Maubec, E., Petrow, P., Scheer-Senyarich, I., Duvillard, P., Lacroix, L., Gelly, J., Certain, A., Duval, X., Crickx, B., Buffard, V., Basset-Seguin, N., Saez, P., Duval-Modeste, A.-B., Adamski, H., Mansard, S., Grange, F., Dompmartin, A., Faivre, S., Mentré, F., & Avril, M.-F. (2011). Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.34.1735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
